FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283169367> ?p ?o ?g. }

• W4283169367 endingPage "108234" @default.
• W4283169367 startingPage "108234" @default.
• W4283169367 abstract "The retinoblastoma gene (RB) was discovered as the first tumor-suppressor gene. It was subsequently shown to be inactivated in most malignant tumors, particularly at the protein level. Therefore, many activated oncogenes as well as inactivated tumor-suppressor genes inactivate the function of the RB protein. I hypothesized that most of the molecular-targeting agents against activated oncogenes may reactivate the function of RB, and proposed screening systems for agents up-regulating the expression of cyclin-dependent kinase inhibitors, such as p15, p27, and p21, which convert the phosphorylated inactive form of the RB protein to the unphosphorylated active form. I termed this screening as RB-reactivator screening. Using the screening systems for agents that up-regulate the expression of p15, p27, and p21, we discovered the novel MEK inhibitor trametinib, the novel RAF/MEK inhibitor CH5126766/RO5126766/VS-6766, and the histone deacetylase inhibitor YM753/OBP-801, respectively. Trametinib exerted remarkable effects in patients with advanced BRAF mutant melanoma, and was approved in the USA as the first-in-class MEK inhibitor (trade name: Mekinist) in 2013. The British Pharmacological Society selected trametinib as the Drug Discovery of the Year in 2013. The combination of trametinib and the BRAF inhibitor dabrafenib was approved for advanced BRAF mutant melanoma in the USA, EU, Japan, and many other countries. Additionally, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the combination of trametinib and dabrafenib in the treatment of patients with advanced BRAF mutant non-small cell lung cancer in 2015, and this combination was subsequently approved in the EU, USA, and Japan. In 2018, this combination was also approved for locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer in the USA after it had been granted Breakthrough Therapy Designation by the FDA. I describe here the characterization of our original screening system, RB-reactivator screening, by which these three molecular-targeting agents that advanced into clinical trials were identified." @default.
• W4283169367 created "2022-06-21" @default.
• W4283169367 creator A5013263645 @default.
• W4283169367 date "2022-08-01" @default.
• W4283169367 modified "2023-10-18" @default.
• W4283169367 title "“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)" @default.
• W4283169367 cites W110544706 @default.
• W4283169367 cites W1596659824 @default.
• W4283169367 cites W1965370740 @default.
• W4283169367 cites W1970419045 @default.
• W4283169367 cites W1973794173 @default.
• W4283169367 cites W1978375723 @default.
• W4283169367 cites W1978925634 @default.
• W4283169367 cites W1980060625 @default.
• W4283169367 cites W1988049858 @default.
• W4283169367 cites W1989830594 @default.
• W4283169367 cites W1997148771 @default.
• W4283169367 cites W2005744028 @default.
• W4283169367 cites W2008836678 @default.
• W4283169367 cites W2010708841 @default.
• W4283169367 cites W2015519364 @default.
• W4283169367 cites W2017593200 @default.
• W4283169367 cites W2020136568 @default.
• W4283169367 cites W2021838661 @default.
• W4283169367 cites W2027202237 @default.
• W4283169367 cites W2037396390 @default.
• W4283169367 cites W2040192374 @default.
• W4283169367 cites W2043033879 @default.
• W4283169367 cites W2048966785 @default.
• W4283169367 cites W2051078890 @default.
• W4283169367 cites W2052214665 @default.
• W4283169367 cites W2055162988 @default.
• W4283169367 cites W2058554042 @default.
• W4283169367 cites W2061413474 @default.
• W4283169367 cites W2064670731 @default.
• W4283169367 cites W2074495613 @default.
• W4283169367 cites W2083304214 @default.
• W4283169367 cites W2086250937 @default.
• W4283169367 cites W2087057471 @default.
• W4283169367 cites W2087821811 @default.
• W4283169367 cites W2096387850 @default.
• W4283169367 cites W2099742439 @default.
• W4283169367 cites W2112463549 @default.
• W4283169367 cites W2118549562 @default.
• W4283169367 cites W2123059506 @default.
• W4283169367 cites W2123687793 @default.
• W4283169367 cites W2123752585 @default.
• W4283169367 cites W2124187885 @default.
• W4283169367 cites W2128390936 @default.
• W4283169367 cites W2128542677 @default.
• W4283169367 cites W2131195100 @default.
• W4283169367 cites W2133177414 @default.
• W4283169367 cites W2136474966 @default.
• W4283169367 cites W2144708319 @default.
• W4283169367 cites W2156078931 @default.
• W4283169367 cites W2157131581 @default.
• W4283169367 cites W2158213613 @default.
• W4283169367 cites W2164452916 @default.
• W4283169367 cites W2166261482 @default.
• W4283169367 cites W2582003601 @default.
• W4283169367 cites W2586117477 @default.
• W4283169367 cites W2604943121 @default.
• W4283169367 cites W2752210999 @default.
• W4283169367 cites W2766581537 @default.
• W4283169367 cites W2914563906 @default.
• W4283169367 cites W2948155539 @default.
• W4283169367 cites W3097863157 @default.
• W4283169367 cites W3164126191 @default.
• W4283169367 cites W782832733 @default.
• W4283169367 doi "https://doi.org/10.1016/j.pharmthera.2022.108234" @default.
• W4283169367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35732246" @default.
• W4283169367 hasPublicationYear "2022" @default.
• W4283169367 type Work @default.
• W4283169367 citedByCount "4" @default.
• W4283169367 countsByYear W42831693672023 @default.
• W4283169367 crossrefType "journal-article" @default.
• W4283169367 hasAuthorship W4283169367A5013263645 @default.
• W4283169367 hasBestOaLocation W42831693671 @default.
• W4283169367 hasConcept C121608353 @default.
• W4283169367 hasConcept C184235292 @default.
• W4283169367 hasConcept C2776062698 @default.
• W4283169367 hasConcept C2776131300 @default.
• W4283169367 hasConcept C2777658100 @default.
• W4283169367 hasConcept C2778472372 @default.
• W4283169367 hasConcept C2778830669 @default.
• W4283169367 hasConcept C2781249067 @default.
• W4283169367 hasConcept C29537977 @default.
• W4283169367 hasConcept C2994587330 @default.
• W4283169367 hasConcept C502942594 @default.
• W4283169367 hasConcept C54355233 @default.
• W4283169367 hasConcept C57074206 @default.
• W4283169367 hasConcept C86803240 @default.
• W4283169367 hasConcept C95444343 @default.
• W4283169367 hasConceptScore W4283169367C121608353 @default.
• W4283169367 hasConceptScore W4283169367C184235292 @default.
• W4283169367 hasConceptScore W4283169367C2776062698 @default.
• W4283169367 hasConceptScore W4283169367C2776131300 @default.
• W4283169367 hasConceptScore W4283169367C2777658100 @default.

• next